Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Company Ltd (NY: BHVN )

79.26 USD +0.01 (+0.01%)
Streaming Delayed Price Updated: 7:38 AM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129
Open 79.25
Bid (Size) 79.20 (2)
Ask (Size) 87.00 (1)
Prev. Close 79.25
Today's Range 79.25 - 79.26
52wk Range 26.56 - 100.77
Shares Outstanding 36,017,573
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
From GlobeNewswire News Releases
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year... 
From PR Newswire

Performance

YTD
-3.24%
-3.24%
1 Month
-6.12%
-6.12%
3 Month
-9.96%
-9.96%
6 Month
+26.73%
+26.73%
1 Year
+71.41%
+71.41%

More News

Read More
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
From PR Newswire
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
From PR Newswire
Biohaven Provides Update On ESG Practices
From PR Newswire
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
From PR Newswire
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
From PR Newswire
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
From Business Wire News Releases
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
From PR Newswire
Recap: Biohaven Pharmaceutical Q4 Earnings
Tags Market News BHVN News
From Benzinga
Biohaven Pharma's BHV-1200 Effective In Neutralizing COVID-19 Variants
Tags FDA COVID/19 Coronavirus BHVN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.